title: A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease. Working Group of the European Society of Paediatric Gastro-enterology and Nutrition (ESPGAN).
abstract: In this paper, a Working Group on Gastro-Oesophageal Reflux discusses recommendations for the first line diagnostic and therapeutic approach of gastro-oesophageal reflux disease in infants and children. All members of the Working Group agreed that infants with uncomplicated gastro-oesophageal reflux can be safely treated before performing (expensive and often unnecessary) complementary investigations. However, the latter are mandatory if symptoms persist despite appropriate treatment. Oesophageal pH monitoring of long duration (18-24 h) is recommended as the investigation technique of choice in infants and children with atypical presentations of gastro-oesophageal reflux. Upper gastro-intestinal endoscopy in a specialised centre is the technique of choice in infants and children presenting with symptoms suggestive of peptic oesophagitis. Prokinetics, still a relatively new drug family, have already obtained a definitive place in the treatment of gastro-oesophageal reflux disease in infants and children, especially if "non-drug" treatment (positional therapy, dietary recommendations, etc.) was unsuccessful. It was the aim of the Working Group to help the paediatrician with this consensus statement and guide-lines to establish a standardised management of gastro-oesophageal reflux disease in infants and children.
authors.affiliation: Kaplan Hospital Rehovot, Israel.
authors.forename: Y
authors.initials: Y
authors.lastname: Vandenplas
authors.forename: A
authors.initials: A
authors.lastname: Ashkenazi
authors.forename: D
authors.initials: D
authors.lastname: Belli
authors.forename: N
authors.initials: N
authors.lastname: Boige
authors.forename: J
authors.initials: J
authors.lastname: Bouquet
authors.forename: S
authors.initials: S
authors.lastname: Cadranel
authors.forename: J P
authors.initials: JP
authors.lastname: Cezard
authors.forename: S
authors.initials: S
authors.lastname: Cucchiara
authors.forename: C
authors.initials: C
authors.lastname: Dupont
authors.forename: K
authors.initials: K
authors.lastname: Geboes
mesh_terms: D002648:Child; D002664:Child Nutritional Physiological Phenomena; D020117:Cisapride; D004941:Esophagitis / Q000175:diagnosis / Q000209:etiology; D004945:Esophagoscopy; D004947:Esophagus / Q000378:metabolism; D005060:Europe; D005762:Gastroenterology; D005764:Gastroesophageal Reflux / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D005769:Gastrointestinal Motility / Q000187:drug effects; D005773:Gastroscopy; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007223:Infant; D010372:Pediatrics; D010880:Piperidines / Q000627:therapeutic use; D011187:Posture; D012955:Societies, Medical
chemical_list: D010880:Piperidines; D020117:Cisapride